Novo Nordisk looks to HEOR data to back Victoza | Pharmafile
Novo Nordisk comments on role of off-label use in Ozempic shortfall
FDA Approves Novo Nordisk's Saxenda as a Treatment for Chronic Weight Management
Type 2 Diabetes and the Role of GLP-1 | Diabetes Education for Patients | novoMEDLINK™
GLP-1 franchise powers progress at Novo Nordisk in 2021
Frontiers | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
New GLP-1 weight loss drugs are about to ship to more American homes
Novo Nordisk Stock: Growing Obesity Epidemic Will Generate Demand (NYSE:NVO) | Seeking Alpha
Long-acting GLP-1 analogue #1
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
Liraglutide seems effective in obesity, says FDA reviewer - PMLiVE
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers - Nørgaard - 2022 - Alzheimer's & Dementia: Translational
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
Novo Nordisk India launches GLP-1 RA, Oral Semaglutide for diabetes management, Health News, ET HealthWorld
Novo Nordisk doesn't feel threatened by GLP-1 rival Lilly
Novo Nordisk's Ozempic is quick out of the blocks, chasing Lilly's Trulicity - PMLiVE
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Novo Nordisk's Rybelsus (semaglutide) is a first oral GLP-1 treatment for type 2 diabetes mellitus - YouTube
Novo Nordisk 2018: Struggling against the tide – PharmaLive
